Infliximab for the therapy of chronic sarcoidosis

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 753-756

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Infliximab; Lungs; Lupus pernio; Sarcoidosis

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXERCISE TOLERANCE; EYE DISEASE; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG SARCOIDOSIS; MONOTHERAPY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RETINOPATHY; SARCOIDOSIS; UNSPECIFIED SIDE EFFECT;

EID: 34248155335     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.753     Document Type: Article

References (16)

1. FEHRENBACH H, ZISSEL G, GOLDMANN T et al.: Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur. Respir. J. (2003) 21(3):421-428.
2. ZIEGENHAGEN MANFRED W, BENNER UDO K, ZISSEL G et al.: Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am. J. Respir. Crit. Care Med. (1997) 156(5):1586-1592.
3. UTZ JP, LIMPER AH, KALRA S et al.: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest (2003) 124(1):177-185.
4. ROBERTS SD, WILKES DS, BURGETT RA, KNOX KS: Refractory sarcoidosis responding to infliximab. Chest (2003) 124(5):2028-2031.
5. DOTY JD, MAZUR JE, JUDSON MA: Treatment of sarcoidosis with infliximab. Chest (2005) 127(3):1064-1071.
6. BAUGHMAN RP, DRENT M, KAVURU M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802.
7. ZABEL P, ENTZIAN P, DALHOFF K, SCHLAAK M: Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. (1997) 155(5):1665-1669.
8. BAUGHMAN RP, LOWER EE, BRADLEY DA, RAYMOND LA, KAUFMAN A: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest (2005) 128(2):1062-1147.
9. GRUTTERS JC, VAN DEN BOSCH JM: Corticosteroid treatment in sarcoidosis. Eur. Respir. J. (2006) 28(3):627-636.
10. PARAMOTHAYAN S, LASSERSON TJ, WALTERS EH: Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syrt. Rev. (2006) 3:CD003536.
11. STERN BJ, SCHONFELD SA, SEWELL C et al.: The treatment of neurosarcoidosis with cyclosporine. Arch. Neurol. (1992) 49(10):1065-1072.
12. HENDERSON CA, ILCHYSHYN A, CURRY AR: Laryngeal and cutaneous sarcoidosis created with methotrexare. J. R. Soc. Med. (1994) 87(10):632-633.
13. MAUST HA, FOROOZAN R, SERGOTT RC et al.: Use of methotrexate in sarcoid-associated optic neuroparhy. Ophthalmology (2003) 11O(3):559-563.
14. JONES E, CALLEN JP: Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J. Am. Acad. Dermatol. (1990) 23(3 Part 1):487-489.
15. SHARMA OP: Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch. Neurol. (1998) 55(9):1248-1254.
16. ZIC JA, HOROWITZ DH, ARZUBIAGA C, KING LE Jr: Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch. Dermatol. (1991) 127(7):1034-1040.